EE200200069A - Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid - Google Patents
Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonidInfo
- Publication number
- EE200200069A EE200200069A EEP200200069A EEP200200069A EE200200069A EE 200200069 A EE200200069 A EE 200200069A EE P200200069 A EEP200200069 A EE P200200069A EE P200200069 A EEP200200069 A EE P200200069A EE 200200069 A EE200200069 A EE 200200069A
- Authority
- EE
- Estonia
- Prior art keywords
- triones
- pyrimidine
- metalloproteinase inhibitors
- metalloproteinase
- inhibitors
- Prior art date
Links
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14854799P | 1999-08-12 | 1999-08-12 | |
| PCT/IB2000/001090 WO2001012611A1 (en) | 1999-08-12 | 2000-08-03 | Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200069A true EE200200069A (et) | 2003-04-15 |
Family
ID=22526231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200069A EE200200069A (et) | 1999-08-12 | 2000-08-03 | Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid |
Country Status (41)
| Country | Link |
|---|---|
| US (1) | US6579982B1 (et) |
| EP (1) | EP1202974B1 (et) |
| JP (1) | JP2003507371A (et) |
| KR (2) | KR20040073608A (et) |
| CN (1) | CN1156454C (et) |
| AR (1) | AR025091A1 (et) |
| AT (1) | ATE309224T1 (et) |
| AU (1) | AU773751B2 (et) |
| BG (1) | BG106406A (et) |
| BR (1) | BR0013081A (et) |
| CA (1) | CA2381551A1 (et) |
| CO (1) | CO5180629A1 (et) |
| CR (1) | CR6565A (et) |
| CZ (1) | CZ2002355A3 (et) |
| DE (1) | DE60023903D1 (et) |
| EA (1) | EA004680B1 (et) |
| EC (1) | ECSP003610A (et) |
| EE (1) | EE200200069A (et) |
| GE (1) | GEP20053424B (et) |
| GT (1) | GT200000137A (et) |
| HK (1) | HK1045995B (et) |
| HN (1) | HN2000000137A (et) |
| HR (1) | HRP20020129A2 (et) |
| HU (1) | HUP0202501A3 (et) |
| IL (1) | IL148035A0 (et) |
| IS (1) | IS6248A (et) |
| MA (1) | MA26812A1 (et) |
| MX (1) | MXPA02001561A (et) |
| NO (1) | NO20020662L (et) |
| NZ (1) | NZ516562A (et) |
| OA (1) | OA12000A (et) |
| PA (1) | PA8498701A1 (et) |
| PE (1) | PE20010491A1 (et) |
| PL (1) | PL353871A1 (et) |
| SK (1) | SK1652002A3 (et) |
| TN (1) | TNSN00169A1 (et) |
| TR (1) | TR200200381T2 (et) |
| UY (1) | UY26285A1 (et) |
| WO (1) | WO2001012611A1 (et) |
| YU (1) | YU6602A (et) |
| ZA (1) | ZA200201070B (et) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| CZ20031083A3 (cs) * | 2000-10-26 | 2004-03-17 | Pfizer Products Inc. | 5-Spiropyrimidin-2, 4, 6-trionové inhibitory metaloproteinasy |
| US6841671B2 (en) | 2000-10-26 | 2005-01-11 | Pfizer Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| AP2001002319A0 (en) * | 2000-10-26 | 2001-12-31 | Pfizer Prod Inc | Pyrimidine-2,4,6-trione metalloproteinase inhibitors. |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| JP2004518723A (ja) | 2001-02-14 | 2004-06-24 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ピリミジンマトリックスメタロプロテイナーゼ阻害剤 |
| PA8539501A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Compuestos triazolo como inhibidores de mmp |
| MXPA03005870A (es) | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibirores de benzotiadiazina de metaloproteinasas de la matriz. |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| JP2003081838A (ja) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | グルコサミン製剤 |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| MXPA04002537A (es) | 2001-10-12 | 2004-05-31 | Warner Lambert Co | Alquinos como inhibidores de metaloproteinasa de matriz. |
| AU2002346729A1 (en) | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| MXPA04010550A (es) * | 2002-04-26 | 2005-01-25 | Pfizer Prod Inc | Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona. |
| JP2005527598A (ja) * | 2002-04-26 | 2005-09-15 | ファイザー・プロダクツ・インク | トリアリール−オキシ−アリール−スピロ−ピリミジン−２，４，６−トリオンメタロプロテイナーゼ阻害剤 |
| AU2003216660A1 (en) * | 2002-04-26 | 2003-11-10 | Pfizer Products Inc. | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| NI200300045A (es) * | 2002-04-26 | 2005-07-08 | Pfizer Prod Inc | Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa. |
| MXPA05001783A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz. |
| AU2003253186A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| AU2003249477A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| MXPA05001786A (es) | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz. |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| WO2004014378A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| WO2004014375A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| CA2497658A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| MXPA05001603A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados monociclicos como inhibidores de metaloproteinasa de matriz. |
| WO2004084903A1 (en) * | 2003-03-27 | 2004-10-07 | F. Hoffmann-La Roche Ag | Use of a trioxopyrimidine for the treatment and prevention of ocular pathologic angiogenesis |
| WO2004084902A1 (en) * | 2003-03-28 | 2004-10-07 | F. Hoffmann-La Roche Ag | Use of a trioxopyrimidine for the treatment of chronic wounds |
| WO2004089294A2 (en) | 2003-04-04 | 2004-10-21 | Incyte Corporation | Compositions, methods and kits relating to her-2 cleavage |
| US20050107350A1 (en) * | 2003-08-22 | 2005-05-19 | Pharmacia Corporation | Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith |
| WO2012014109A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US20150366275A1 (en) * | 2014-06-19 | 2015-12-24 | Gyula Cserfoi | Wearable Signaling Device |
| GB201705255D0 (en) | 2017-03-31 | 2017-05-17 | Univ I Tromsø - Norges Arktiske Univ | Bioactive cyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0000505A3 (en) * | 1996-08-28 | 2001-12-28 | Procter & Gamble | Saturated 7-9 membered heterocyclic n-hydroxycarboxamide derivatives and pharmaceutical compositions containing them |
| EP0989982B1 (en) * | 1997-06-21 | 2005-08-17 | Roche Diagnostics GmbH | Barbituric acid derivatives with antimetastatic and antitumor activity |
-
2000
- 2000-07-20 HN HN2000000137A patent/HN2000000137A/es unknown
- 2000-07-20 PA PA20008498701A patent/PA8498701A1/es unknown
- 2000-08-03 CN CNB008113920A patent/CN1156454C/zh not_active Expired - Fee Related
- 2000-08-03 BR BR0013081-8A patent/BR0013081A/pt not_active IP Right Cessation
- 2000-08-03 KR KR10-2004-7011899A patent/KR20040073608A/ko not_active Ceased
- 2000-08-03 HU HU0202501A patent/HUP0202501A3/hu unknown
- 2000-08-03 PL PL00353871A patent/PL353871A1/xx not_active Application Discontinuation
- 2000-08-03 GE GE4688A patent/GEP20053424B/en unknown
- 2000-08-03 TR TR2002/00381T patent/TR200200381T2/xx unknown
- 2000-08-03 OA OA1200200030A patent/OA12000A/en unknown
- 2000-08-03 DE DE60023903T patent/DE60023903D1/de not_active Expired - Lifetime
- 2000-08-03 JP JP2001517509A patent/JP2003507371A/ja active Pending
- 2000-08-03 KR KR1020027001880A patent/KR20020047119A/ko not_active Abandoned
- 2000-08-03 IL IL14803500A patent/IL148035A0/xx unknown
- 2000-08-03 MX MXPA02001561A patent/MXPA02001561A/es active IP Right Grant
- 2000-08-03 YU YU6602A patent/YU6602A/sh unknown
- 2000-08-03 EA EA200200058A patent/EA004680B1/ru not_active IP Right Cessation
- 2000-08-03 HK HK02107534.6A patent/HK1045995B/zh not_active IP Right Cessation
- 2000-08-03 CZ CZ2002355A patent/CZ2002355A3/cs unknown
- 2000-08-03 CA CA002381551A patent/CA2381551A1/en not_active Abandoned
- 2000-08-03 HR HR20020129A patent/HRP20020129A2/xx not_active Application Discontinuation
- 2000-08-03 SK SK165-2002A patent/SK1652002A3/sk unknown
- 2000-08-03 WO PCT/IB2000/001090 patent/WO2001012611A1/en not_active Ceased
- 2000-08-03 EP EP00946235A patent/EP1202974B1/en not_active Expired - Lifetime
- 2000-08-03 NZ NZ516562A patent/NZ516562A/xx unknown
- 2000-08-03 EE EEP200200069A patent/EE200200069A/et unknown
- 2000-08-03 AU AU60105/00A patent/AU773751B2/en not_active Ceased
- 2000-08-03 AT AT00946235T patent/ATE309224T1/de not_active IP Right Cessation
- 2000-08-04 CO CO00058849A patent/CO5180629A1/es not_active Application Discontinuation
- 2000-08-09 US US09/635,156 patent/US6579982B1/en not_active Expired - Fee Related
- 2000-08-09 UY UY26285A patent/UY26285A1/es not_active Application Discontinuation
- 2000-08-09 EC EC2000003610A patent/ECSP003610A/es unknown
- 2000-08-10 GT GT200000137A patent/GT200000137A/es unknown
- 2000-08-10 AR ARP000104130A patent/AR025091A1/es unknown
- 2000-08-10 PE PE2000000811A patent/PE20010491A1/es not_active Application Discontinuation
- 2000-08-11 TN TNTNSN00169A patent/TNSN00169A1/fr unknown
-
2002
- 2002-01-25 IS IS6248A patent/IS6248A/is unknown
- 2002-01-29 CR CR6565A patent/CR6565A/es not_active Application Discontinuation
- 2002-02-07 MA MA26512A patent/MA26812A1/fr unknown
- 2002-02-07 ZA ZA200201070A patent/ZA200201070B/en unknown
- 2002-02-11 NO NO20020662A patent/NO20020662L/no not_active Application Discontinuation
- 2002-02-12 BG BG06406A patent/BG106406A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20031853L (no) | Spiro-pyrimidin-2,4,6-trion metalloproteinaseinhibitorer | |
| DK1181017T3 (da) | Metalloproteaseinhibitorer | |
| EE200100502A (et) | Ühendid | |
| ATE512949T1 (de) | Reninhemmer | |
| MA25499A1 (fr) | Contacteur-disjoncteur. | |
| PT1194404E (pt) | Inibidores de aspartil-protease | |
| DE60035039D1 (de) | Renin inhibitoren | |
| MA26849A1 (fr) | 4-pyridinyle-n-acyl-l-phenylalanines. | |
| NO20014243L (no) | Dihetero-substituerte metalloproteaseinhibitorer | |
| ITBO990359A0 (it) | Elettromandrino . | |
| ID29533A (id) | Senyawa-senyawa kalsilitik | |
| DE60029755D1 (de) | Congawandschutz. | |
| NO20020466D0 (no) | Kalsilytiske forbindelser | |
| NO20014262D0 (no) | Tiazoloindolinon-forbindelser | |
| ITBO990358A0 (it) | Elettromandrino . | |
| IT1311662B1 (it) | Struttura di calzatura. | |
| ID29984A (id) | Senyawa-senyawa bis-stirilbifenil | |
| NO991585D0 (no) | Trekkanordning | |
| ID27139A (id) | Bertukol kusmargono | |
| ES1044838Y (es) | Friegasuelos. | |
| ITSS990004V0 (it) | Piramide - ricordo. | |
| ATA732000A (de) | Kachelofen | |
| ES1044490Y (es) | Piñata. | |
| ES1043620Y (es) | Urna-columbario. | |
| ES1044797Y (es) | Collar-bozal antitiro. |